Cargando…
Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
Satralizumab, a monoclonal antibody against interleukin-6 receptors, has been approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD). Several reports have described the effectiveness of satralizumab against neuropathic pain in patients with NMOSD, but its effects on painful ton...
Autores principales: | Uzawa, Akiyuki, Mori, Masahiro, Iwai, Yuta, Masuda, Hiroki, Kuwabara, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556229/ https://www.ncbi.nlm.nih.gov/pubmed/35135926 http://dx.doi.org/10.2169/internalmedicine.9036-21 |
Ejemplares similares
-
Satralizumab for neuromyelitis optica spectrum disorder
Publicado: (2021) -
Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine
por: Uzawa, Akiyuki, et al.
Publicado: (2011) -
Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis
por: Masuda, Hiroki, et al.
Publicado: (2020) -
Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Masuda, Hiroki, et al.
Publicado: (2022) -
Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica
por: Uzawa, Akiyuki, et al.
Publicado: (2010)